Shares of Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) have been assigned an average rating of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.67.
A number of research firms have commented on AFIB. William Blair reissued a “market perform” rating on shares of Acutus Medical in a research note on Thursday, March 31st. Canaccord Genuity Group reduced their price objective on Acutus Medical from $10.00 to $3.00 and set a “hold” rating on the stock in a research note on Friday, January 14th. BTIG Research lowered Acutus Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, January 20th. Zacks Investment Research lowered Acutus Medical from a “hold” rating to a “sell” rating in a research note on Monday, April 4th. Finally, UBS Group lowered Acutus Medical from a “buy” rating to a “hold” rating in a research note on Friday, January 14th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AFIB. Dimensional Fund Advisors LP acquired a new position in Acutus Medical in the fourth quarter valued at about $37,000. Wells Fargo & Company MN grew its stake in Acutus Medical by 241.0% in the fourth quarter. Wells Fargo & Company MN now owns 15,866 shares of the company’s stock valued at $54,000 after acquiring an additional 11,213 shares during the period. Royal Bank of Canada grew its stake in Acutus Medical by 120.7% in the second quarter. Royal Bank of Canada now owns 3,743 shares of the company’s stock valued at $64,000 after acquiring an additional 2,047 shares during the period. Walleye Trading LLC acquired a new position in Acutus Medical in the fourth quarter valued at about $77,000. Finally, Deutsche Bank AG grew its stake in Acutus Medical by 24.1% in the third quarter. Deutsche Bank AG now owns 11,358 shares of the company’s stock valued at $100,000 after acquiring an additional 2,203 shares during the period. Institutional investors and hedge funds own 72.28% of the company’s stock.
Acutus Medical (NASDAQ:AFIB – Get Rating) last announced its quarterly earnings data on Wednesday, March 30th. The company reported ($1.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.21). The firm had revenue of $4.36 million for the quarter, compared to analyst estimates of $4.30 million. Acutus Medical had a negative return on equity of 116.28% and a negative net margin of 681.71%. Sell-side analysts expect that Acutus Medical will post -3.17 earnings per share for the current fiscal year.
Acutus Medical Company Profile (Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.